AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

Search

Indivior PLC

Fermé

829.5 -1.54

Résumé

Variation du prix de l'action

24h

Actuel

Min

815

Max

841.5

Chiffres clés

By Trading Economics

Revenu

-19M

47M

Ventes

-33M

266M

P/E

Moyenne du Secteur

330

54.533

BPA

0.41

Marge bénéficiaire

17.669

Employés

1,030

EBITDA

-30M

76M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+20.19% upside

Dividendes

By Dow Jones

Prochains Résultats

24 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

259M

1.1B

Ouverture précédente

831.04

Clôture précédente

829.5

Indivior PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 mai 2025, 23:25 UTC

Actions en Tendance

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mai 2025, 21:57 UTC

Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mai 2025, 21:29 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Operations in Uruguay

21 mai 2025, 21:01 UTC

Principaux Mouvements du Marché

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mai 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mai 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mai 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mai 2025, 23:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mai 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mai 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mai 2025, 23:28 UTC

Résultats

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mai 2025, 23:27 UTC

Résultats

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mai 2025, 23:23 UTC

Acquisitions, Fusions, Rachats

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mai 2025, 23:22 UTC

Actualités

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 mai 2025, 23:22 UTC

Acquisitions, Fusions, Rachats

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mai 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mai 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mai 2025, 23:04 UTC

Actualités

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 mai 2025, 21:46 UTC

Actualités

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 mai 2025, 21:42 UTC

Actualités
Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mai 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Ops in Uruguay

21 mai 2025, 21:07 UTC

Actualités

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mai 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Comparaison

Variation de prix

Indivior PLC prévision

Objectif de Prix

By TipRanks

20.19% hausse

Prévisions sur 12 Mois

Moyen 1,014.42 GBX  20.19%

Haut 1,100 GBX

Bas 968.247 GBX

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.